Summary Inhibition of protein kinase C (PKC) is discussed as a new approach for overcoming multidrug resistance (MDR) in cancer chemotherapy. For evaluation of this concept we applied the bisindolylmaleimide GF 109203X, which shows a highly selective inhibition of PKC isozymes a, /31, ,B2, y, 6 and e in vitro. The efficacy of this compound in modulation of MDR was examined using several P-glycoprotein (P-gp)-overexpressing cell lines including a MDRI-transfected HeLa clone, and was compared with the activities of dexniguldipine-HCl (DNIG) and dexverapamil-HCl (DVER), both of which essentially act via binding to P-gp. As PKCa has been suggested to play a major role in P-gp-mediated MDR, cell lines exhibiting different expression levels of this PKC isozyme were chosen. On crude PKC preparations or in a cellular assay using a cfos(-71 I)CAT-transfected NIH 3T3 clone, the inhibitory qualities of the bisindolylmaleimide at submicromolar concentrations were demonstrated. At up to 1 gm final concentrations of the PKC inhibitor GF 109203X, a concentration at which many PKC isozymes should be blocked substantially, no cytotoxic or MDR-reversing effects whatsoever were seen, as monitored by 72 h tetrazolium-based colorimetric MTT assays or a 90 min rhodamine 123 accumulation assay. Moreover, depletion of PKCa by phorbol ester in HeLa-MDR1 transfectants had no influence on rhodamine 123 accumulation after 24 or 48 h. MDR reversal activity of GF 109203X was seen at higher final drug concentrations, however. Remarkably, [3H]vinblastine-sulphate binding competition experiments using P-gp-containing crude membrane preparations demonstrated similar dose dependencies as found for MDR reversion by the three modulators, i.e. decreasing efficacy in the series dexniguldipine-HCl>dexverapamil-HCl>GF 109203X. Similar interaction with the P-gp in the micromolar concentration range was revealed by competition of GF 109203X with photoincorporation of [3H]azidopine into P-gp-containing crude membrane preparations. No significant effect of the PKC inhibitor on MDR1 expression was seen, which was examined by cDNA-PCR. Thus, the bisindolylmaleimide GF 109203X probably influences MDR mostly via direct binding to P-gp. Our work identifies the bisindolylmaleimide GF 109203X as a new type of drug interacting with P-gp directly, but does not support the concept of a major contribution of PKC to a P-gp-associated MDR, at least using the particular cellular model systems and the selective, albeit general, PKC inhibitor GF 109203X.
Specific sites of the human P-gp have been shown to be phosphorylated Say PKC (Chambers et al., 1993) , and an interdependence of P-gp phosphorylation, PKC activity, P-gp activity and multidrug resistance is indicated by the work of several groups (Hamada et al., 1987; Yu et al., 1991; Chambers et al., 1992; Bates et al., 1993) . In particular, PKCa appears to be involved in activation of the drug transporter (Yu et al., 1991; Ahmad and Glazer, 1993) . Moreover, PKC has been discussed as part of a stress response activating MDR] gene expression (Chaudhary and Roninson, 1993; Grunicke et al., 1994) . Thus, inhibition of PKC has emerged as a new approach for overcoming MDR in cancer chemotherapy. So far, rather non-specific kinase inhibitors have been used to investigate the involvement of PKC in MDR. The bisindolylmaleimide GF 109203X, which is identical to Go 6850 (Figure 2a ), shows highly selective inhibition of many PKC isozymes in vitro. Thus, using preparations of PKCa, -,B1, -/32, -y, -6 and -s from recombinant cell clones, IC50 values between 20 nm and 200 nM were measured. Other kinases were affected at distinctly higher concentrations (Toullec et al., 1991; Martiny-Baron et al., 1993; Hartenstein et al., 1993) , e.g. PKC 4 (IC50 5.8 gM), PKA (cAMP-dependent protein kinase; IC50 33 gM), IC50 4.6 gM) or tyrosine kinases (IC50 94 /uM). The compound GF 109203X retains its PKC inhibitory quality in cellular assays (Toullec et al., 1991; Heikkila et al., 1993; Le Panse et al., 1994) . This PKC inhibitor is therefore suited to address the issue.
In principle, a chemosensitiser might affect P-gp-associated MDR (1) by direct interaction with the P-gp; (2) by modulation of P-gp activity indirectly, e.g. via inhibition of phosphorylation by protein kinases; or (3) by altering MDR1/P-gp gene expression. In order to discriminate between these possible mechanisms we applied different methodical approaches for testing the MDR modulating activities of three different types of compounds on a series of cell lines expressing P-gp and PKCa at various levels. Thus, the effects of the bisindolylmaleimide PKC inhibitor GF 109203X were compared with the activities of the enantiomeric pure dihydropyridine dexniguldipine-HCl (DNIG, B8509-035) and the phenylalkylamine dexverapamil-HCl (DVER; for structures see Figure 2b and c). The last two compounds modulate a P-gp-associated MDR accordingly by direct interaction with P-gp (Yusa and Tsuruo, 1989; Hofmann et al., 1995; Borchers et al., 1995) . DNIG also exhibits PKC-inhibitory qualities (Uberall et al., 1991) , however only at about 100-fold higher concentrations compared with the bisindolylmaleimide GF 109203X. Thus, it appeared important to elucidate the relevance of PKC on P-gp-associated MDR by comparing MDR reversal efficacies of a specific PKC inhibitor and structurally different drugs essentially interacting with P-gp directly. Our approach might help to evaluate the concept of developing such drugs for overcoming MDR in the clinics. (Uberall et al., 1991; .
Western immunoblotting
The preparations of the various protein fractions and the transfer onto Immobilon-P membranes (Millipore, Eschborn, Germany) were performed as described (Kimmig et al., 1990; Neumann et al., 1992; Hofmann et al., 1995 Figure 10 ). While staurosporine, as expected, inhibited cell growth in the nanomolar concentration range, the bisindolylmaleimide GF 109203X did not produce any anti-proliferative activity up to 2 jgM, or even 10 gM, depending on the cell line. DNIG showed anti-proliferative/cytotoxic activity at similar concentrations to GF 109203X, while dexverapamil-HCl usually did not stop cellular growth completely up to a final concentration of 100 gM. Interestingly, we observed an association of P-gp expression with the sensitivity of the cell lines towards these agents. Thus, a collateral sensitivity of CCRF ADR 5000 cells to DNIG and dexverapamil-HCl was seen (a detailed analysis of this phenomenon will be published elsewhere). In contrast, an up to 8-fold resistance of MDR Figure 2a . DNIG produced only a partial inhibition at concentrations higher than 10 ,uM ( Figure  2b ), but dexverapamil-HCl was virtually inactive (Figure 2c ). Figure 4 demonstrates the dose-dependent modulation of the vincristine resistance of CCRF VCR 1000 cells by DNIG applying the 72 h MTT assay. Figure Because the MDR sublines of the human T-lymphoblastoid cell line CCRF-CEM show rather low expression of PKCa, we additionally investigated the MDR reversal capacity of the compound GF 109203X on cell lines exhibiting distinct expression of this PKC isozyme. Therefore, the MDRI/P-gp transfectant HeLa subclone HeLa-MDR1 and the cell line KB 8.5 were included in the study. Figure 7a shows the dose-dependent reversion of vincristine or doxorubicin resistances of HeLa-MDRI cells by GF 109203X or DNIG respectively. In good correspondence to the data shown above, the PKC inhibitor produced effects only at concentrations higher than 1^u M, in contrast to DNIG. Remarkably, however, using GF 109203X a complete reversal of both resistances was achieved, while DNIG could (Figure 10 ). Under these conditions the rhodamine 123 transport was measured in the presence or absence of the PKC inhibitor GF 109203X or DNIG respectively. No influence of the PKC depletion whatsoever could be observed however (Figure 11) , whereas DNIG at a 1 ,UM final concentration produced a strong increase of the cellular dye content as expected. Inhibition of PKC appears to be an intriguing new approach for overcoming MDR eventually affecting two completely different mechanisms simultaneously: (1) the inactivation of P-gp via alteration of its phosphorylation status; and (2) the suppression of MDR1 gene expression. The latter seems to be especially attractive in view of reports on an anti-cancer drug-mediated MDRl gene induction (Gekeler et al., 1988; Kohno et al., 1989; Chaudhary and Roninson, 1993) which might represent a PKC-triggered stress response and could therefore be attenuated by PKC inhibitors possibly given together with anti-cancer drugs (Chaudhary and Roninson, 1993; Grunicke et al., 1994) . So far, rather nonspecific PKC inhibitors like staurosporine or the isoquinoline sulphonamide derivative H7 were used to investigate the issue (Chaudhary and Roninson, 1993) . Therefore, we applied the highly specific PKC inhibitor GF 109203X. Because of the assumed involvement of PKCa in P-gp activity (Yu et al., 1991; Ahmad and Glazer, 1993) , cell lines exhibiting different levels of PKCa expression were examined. To substantiate the data further, some experiments using the phorbol ester TPA for depletion of PKCc were performed. Other PKC isozymes might be relevant for P-gp phosphorylation, however. It has been described that phorbol ester treatment also down-modulates PKC5 and PKCe, but leaves PKCC Nonetheless, using the HeLa-MDR1 transfectant, downmodulation of PKC by TPA showed virtually no effect after 24 h or 48 h. Similar findings were published recently using the P-gp overexpressing hamster MDR cell line CHRC5 and PDBu for down-modulation of PKC (Epand and Stafford, 1993) , or the P-gp and PKCa overexpressing human breast carcinoma cell line MCF-7TH and TPA or bryostatin 1 for down-modulation of PKC isozymes a and (partly) £ (Scala et al., 1995) . We and others (Toullec et al., 1991; Heikkila et al., 1993; Le Panse et al., 1994) have shown that the compound GF 109203X retains its PKC-inhibitory quality in assays using vital cells, as distinct inhibition was seen there at final concentrations below 1 gM. Some variation, however, of PKC-inhibitory qualities of the compound GF 109203X in various cellular assays could be explained by different expression levels of Ca2+-dependent or Ca2'-independent PKC isozymes (Martiny- Baron et al., 1993; Le Panse et al., 1994) .
As we excluded any modulation of MDR1 gene expression by the bisindolylmaleimide after a 24 h incubation of two different types of MDR cells, i.e. a Tlymphoblastoid CCRF-CEM subline and an adenocarcinoma KB subline (Figure 12) , there is no reason to assume an involvement of the PKC isozymes oa, #f1, #2, y, ( (1991) . Thus, at present we cannot state whether phosphorylation of P-gp actually occurs in the cell lines investigated here and at which final concentrations the compound GF 109203X might influence in a cellular assay the phosphorylation of P-gp and/or other cellular PKC substrates. Moreover, a contribution to P-gp activity of particular PKC isozymes like PKC; (as proposed recently by Bates et al., 1993) , poorly affected by GF 109203X, cannot be excluded. However, no influence of P-gp phosphorylation on P-gp transport fumction was observed by Scala et al. (1995) . Moreover, an altered P-gp in which the serines at positions 661, 667, 671, 675 and 683 were replaced by non-phosphorylatable alanine residues showed neither significant [39Porthophosphate incorporation nor a significantly disturbed transport function (Germann et al., 1996) . Altogether, there is no experimental evidence for a major contribution of P-gp phosphorylation to MDR in a variety of cell types and transfectants.
As it was shown previously (Toullec et al., 1991) that the bisindolylmaleimide GF 109203X competes with ATP at PKC, we speculate on an interaction of the drug with the ATP binding site(s) of P-gp as well, which might also be true for the reversal by GF 109203X of the MDR mediated by the newly identified ABC (ATP binding cassette) drug transporter MRP (multidrug resistance associated protein) . From our data it seems obvious, however, that chemosensitisers binding to P-gp with high affinity (such as DNIG) may be particularly valuable for clinical use as MDR modulators. Nonetheless, the bisindolylmaleide represents a new tool structure possibly binding to a site on P-gp different from the binding site of DNIG, which supposedly acts as an allosteric inhibitor of P-gp according to Ferry et al. (1992) and Malkhandi et al. (1994 
